Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review

In conclusion, the evidence thus far has not been significant enough for the American College of Cardiology to recommend the incorporation of oral anticoagulants in the management of stable ischemic heart disease patients, in contrast to aspirin and clopidogrel. As the antithrombotic and antiischemic properties of these newer agents seem evident, so does their potential for increase in risk of bleeding events. Doctors have to individually tailor antithrombotic medication decisions based on the patient ’s risk-benefit profile.
Source: Current Cardiology Reports - Category: Cardiology Source Type: research